

REPOS THERAPEUTICS INC.  
Form 8-K  
March 20, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): March 20, 2009  
Repos Therapeutics Inc.  
(Exact name of registrant as specified in its charter)**

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>001-15281</b> (Commission File Number)	<b>76-0233274</b> (I.R.S. Employer Identification No.)
--	--	--

**2408 Timberloch Place, Suite B-7  
The Woodlands, Texas 77380  
(Address of principal  
executive offices  
and zip code)  
(281) 719-3400  
(Registrant's telephone  
number, including area  
code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure**

On March 20, 2009, Repros Therapeutics Inc. (the Company ) announced that it will hold its annual meeting of shareholders on May 20, 2009, at 8:00 a.m. (Pacific Time) at the Inn at Rancho Santa Fe, Rancho Santa Fe, CA. Shareholders of record as of March 23, 2009 will be entitled to attend and vote at the meeting.

**Item 8.01. Other Information**

A copy of the Company s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated March 20, 2009

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: March 20, 2009

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.  
Vice President, Business Development  
and Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated March 20, 2009